Ravulizumab for treatment of neuromyelitis optica spectrum disorder

Ravulizumab is in clinical development for the treatment of neuromyelitis optica spectrum
disorder (NMOSD) NMOSD is a rare autoimmune disease where the immune system attacks the
nerves in the eyes and central nervous system (CNS), which can result in weakness, paralysis, pain,
blindness, and premature death. The condition often has frequent relapses which can result in
progressive disabilities for the patient. New treatment options could decrease frequency and
intensity of relapses for patients, increasing overall survival for patients.